Iraqi Journal of Pharmacy

Abstract

Background: Dyslipidemia is common in patients with type 2 diabetes mellitus and is regarded as independent risk factor for cardiovascular disease.
The aim of this study was to evaluate the efficacy and safety of atorvastatin for the treatment of dyslipidemia in type 2 diabetics using either metformin or glibenclamide as oral hypoglycemic agents.
Materials and methods: Fourty five type 2 diabetic patients diagnosed with dyslipidemia met the study criteria and received 20 mg/day atorvastatin, then followed after 2 months. The various biochemical parameters studied included glycated hemoglobin (HbA1c), fasting serum glucose levels (FSG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and atherogenic index (AI).
Results showed that atorvastatin in both studied groups caused significant reduction in all measured parameters with an elevation in HDL, but this effect was obvious and more significant in patients using metformin than those using glibenclamide.
Conclusion: This study concluded that the combination of atorvastatin and metformin was more effective on lipid profile and glucose level than atorvastatin plus glibenclamide in type 2 diabetic patients with dyslipidemia.